11.06
+0.27(+2.50%)
Currency In USD
| Previous Close | 10.79 |
| Open | 10.84 |
| Day High | 11.12 |
| Day Low | 10.75 |
| 52-Week High | 12.49 |
| 52-Week Low | 5.41 |
| Volume | 545,862 |
| Average Volume | 1.99M |
| Market Cap | 962.41M |
| PE | -4.46 |
| EPS | -2.48 |
| Moving Average 50 Days | 10.63 |
| Moving Average 200 Days | 7.82 |
| Change | 0.27 |
If you invested $1000 in Kura Oncology, Inc. (KURA) 10 years ago, it would be worth $1,612.24 as of December 25, 2025 at a share price of $11.06. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $325.01 as of December 25, 2025 at a share price of $11.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
GlobeNewswire Inc.
Dec 08, 2025 3:30 PM GMT
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and overall survival not yet reached in newly diagnosed N
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
GlobeNewswire Inc.
Dec 03, 2025 1:32 PM GMT
Event Scheduled for December 8, 2025 at 12:30 PM ETSAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, t
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
GlobeNewswire Inc.
Dec 02, 2025 1:02 PM GMT
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sa